Department of Neurosurgery, Preston A. Wells Jr. Center for Brain Tumor Therapy, University of Florida, Gainesville, Florida.
Department of Mechanical and Aerospace Engineering, University of Florida, Gainesville, Florida.
Neuro Oncol. 2020 Sep 29;22(9):1249-1261. doi: 10.1093/neuonc/noaa116.
In oncology, "immunotherapy" is a broad term encompassing multiple means of utilizing the patient's immune system to combat malignancy. Prominent among these are immune checkpoint inhibitors, cellular therapies including chimeric antigen receptor T-cell therapy, vaccines, and oncolytic viruses. Immunotherapy for glioblastoma (GBM) has had mixed results in early trials. In this context, the past, present, and future of immune oncology for the treatment of GBM was discussed by clinical, research, and thought leaders as well as patient advocates at the first annual Remission Summit in 2019. The goal was to use current knowledge (published and unpublished) to identify possible causes of treatment failures and the best strategies to advance immunotherapy as a treatment modality for patients with GBM. The discussion focuses on past failures, current limitations, failure analyses, and proposed best practices moving forward.
在肿瘤学中，“免疫疗法”是一个广泛的术语，涵盖了多种利用患者免疫系统来对抗恶性肿瘤的方法。其中突出的有免疫检查点抑制剂、嵌合抗原受体 T 细胞疗法等细胞疗法、疫苗和溶瘤病毒。免疫疗法治疗胶质母细胞瘤（GBM）在早期试验中的结果喜忧参半。在这种情况下，临床、研究和思想领袖以及患者权益倡导者在 2019 年的第一次年度缓解峰会上讨论了免疫肿瘤学在治疗 GBM 方面的过去、现在和未来。其目标是利用现有知识（已发表和未发表的）来确定治疗失败的可能原因，以及将免疫疗法作为 GBM 患者的治疗方法的最佳策略。讨论集中在过去的失败、当前的局限性、失败分析以及未来的最佳实践。
